Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Stock market indices remain buoyant
Tue, 13 Mar 01:30 pm

Indian stock markets continued to remain bullish in the last two trading hours on the back of sustained buying by heavyweights. All the sectoral indices are trading positive. Metal, oil & gas and consumer good stocks are the biggest gainers.

The BSE-Sensex is trading up 196 points and NSE-Nifty is trading up 60 points. Both BSE Mid cap and BSE Small cap indices are up by 1% and 0.8%, respectively. The rupee is trading at 49.8 to the US dollar.

Majority of the Indian pharma stocks are trading positive with Fresenius Kabi (up 4.4%) and Strides Acrolab (up 4.4%) being the biggest gainers. As per a leading financial daily, biotechnology major Biocon has terminated its agreement with Pfizer Inc. for commercialization of the former's biosimilar versions of Insulin and Insulin analog products. The agreement has come to an end as both the companies had their individual priorities for their respective biosimilar businesses. After discontinuance of the alliance and thereby termination of license rights to Pfizer, all insulin distributed under the brand name Univia and Glarvia will be commercially manufactured, supplied and marketed exclusively by Biocon. It must be noted that Biocon's alliance with Pfizer was part of its strategy to enter the European biosimilars market post 2015. The alliance was also one of the reasons why Biocon chose to divest its stake in AxiCorp, which was earlier acquired as a base from which to capitalize on the biosimilars opportunity in Europe. The stock is down 5.2%.

Energy stocks are trading mixed with Gas Authority of India Ltd. (GAIL) and Essar Oil leading the gainers and Petronet LNG and Castrol trading the weakest. As per a leading financial daily, GAIL will commission Dabhol LNG (liquefied natural gas) terminal by the end of March or early April. GAIL had mechanically completed the plant in late 2010. It will become fully operational only by 2013-2014 once breakwater facilities are completed. The company is in talks for long term LNG tie ups for the terminal and will also be using spot LNG. GAIL owns 35.2% in Ratnagiri Gas and Power Limited (RGPL) which in turn owns a 1,967 Megawatt (MW) power plant and the LNG import terminal that has an annual capacity of 5 million tonnes(MT).

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Stock market indices remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.